ArticleOncology letters2026
KRT14 activated by transcription factor E2F1 promotes bladder cancer progression.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer is one of the most common cancers in the world, and its high malignancy threatens human health. Therefore, it is vital to explore new therapeutic targets for the early diagnosis and prognosis evaluation of bladder cancer. Keratin 14 (KRT14) is the oncogene of numerous cancers, but its role and mechanism in bladder cancer are not completely clear. The present study aimed to assess the molecular mechanism of KRT14 in bladder cancer. Bioinformatics analyses were performed to screen KRT14 as an oncogene in bladder cancer. Moreover, KRT14 small interfering RNA and KRT14 overexpression plasmids were transfected into 5637 and RT4 bladder cancer cells. Subsequently, Transwell, Cell Counting Kit-8 and cell colony formation assays were performed to assess changes in cell phenotype. Finally, bioinformatics analysis was performed to screen for transcription factors of KRT14. The results demonstrated that KRT14 was highly expressed in bladder cancer tissues and cell lines, and its expression was associated with a poor prognosis. KRT14 knockdown suppressed proliferation, migration and invasion of 5637 and RT4 cells, whereas ectopic KRT14 overexpression demonstrated the inverse phenotypic changes. E2F transcription factor 1 (E2F1) is an upstream transcription factor of KRT14 and the effects of KRT14 silencing on 5637 cell migration and invasion were attenuated by E2F1 overexpression. In addition, Gene Set Cancer Analysis, drug sensitivity correlation analysis and molecular docking simulation predicted that afatinib, erlotinib and vandetanib may serve as candidate small molecules with potential binding affinity to KRT14. This provides preliminary clues for developing KRT14-intervening agents for bladder cancer. In conclusion, KRT14 is an oncogenic gene that promotes bladder cancer progression upon transcriptional activation by the upstream transcription factor E2F1. Its high expression is associated with poor prognosis, supporting its potential as a prognostic biomarker and therapeutic target in bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.